KYKathleen J. Yost

Kathleen J. Yost

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kathleen J. Yost has a total of 125 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparison of the Association of Area‐Based Deprivation Indices With Hypertension and Diabetes Control Outcomes

    by Samuel T. Savitz, Jill M. Killian, Kathleen J. Yost, Jennifer St. Sauver, Alanna M. Chamberlain

    Background: Area‐based deprivation indices have been linked to hypertension and diabetes outcomes, but limited information exists about their relative performance. We compared 2 area‐based deprivation measures (Area Deprivation Index and Yost Index) as risk factors for hypertension and diabetes control. Methods: This cohort study identified adults with hypertension or diabetes in a 19‐county region of Southeast Minnesota covered by the Rochester Epidemiology Project. The deprivation indices were operationalized as quintiles for state and national ranks. We assessed agreement using the weighted kappa statistic. We used modified Poisson regression to evaluate associations of the deprivation indices with blood pressure or diabetes control in 2022. We compared relative model fit using the area under the receiver operating characteristic curve. Results: We identified 67 386 individuals with hypertension and 30 435 with diabetes. There was moderate to substantial agreement between indices, but the agreement was higher for the state rank (weighted kappa 0.68 for both cohorts) than the national rank (0.54 for both). Although the indices were not associated with hypertension control, greater deprivation was associated with worse diabetes control for the Yost Index (relative risk [RR], 1.21 [95% CI, 1.07–1.38]) and Area Deprivation Index (RR, 1.39 [95% CI, 1.12–1.73]) national ranks. The full‐model area under the receiver operating characteristic curve was similar across indices but differed across cohorts with worse fit for hypertension (0.53 for both) than diabetes (0.63 for both). Conclusions: Two common area‐based deprivation indices had similar strength of association with diabetes control, suggesting that either index would be appropriate for researching and developing interventions for diabetes control.

  • Development and Validation of Emoji Response Scales for Assessing Patient-Reported Outcomes

    by Carrie A. Thompson, Paul J. Novotny, Kathleen Yost, Alicia C. Bartz, Lauren Rogak, Amylou C. Dueck

    PURPOSE: Emoji are digital images or icons used to express an idea or emotion in electronic communication. The purpose of this study was to develop and evaluate the psychometric properties of two patient-reported scales that incorporate emoji. METHODS: The Emoji Response Scale developed for this study has two parts: the Emoji-Ordinal and Emoji-Mood scales. A pilot study was designed to validate the ordinal nature of the Emoji-Ordinal Scale. Twenty patients were shown all possible pairs of five emoji and asked to select the most positive from each pair. The psychometric ordering was assessed using Coombs unfolding and Thurstone scaling. A separate pilot study was designed to determine which emoji to include in the Emoji-Mood Scale. Ten common feelings experienced by patients with cancer were chosen by the study team. Patients and providers were asked to select the one emoji that best represented each feeling from the selection. The most commonly selected emotions and representative emoji were chosen for the Emoji-Mood Scale. In a randomized study of 294 patients, Spearman correlations, Wilcoxon tests, and Bland-Altman analyses determined the construct validity of the scales compared with Linear Analog Scale Assessments (LASA) and Patient-Reported Outcomes Measurement Information System (PROMIS) scores. RESULTS: Ninety-five percent of patients selected the same ordering among the ordinal emoji, and Thurstone scaling confirmed the ordinal nature of the response scale. The construct validity of the scales was high with correlations between the Emoji-Ordinal Scale and the LASA scale of 0.70 for emotional well-being, 0.72 for physical well-being, 0.74 for overall quality of life, and –0.81 for fatigue. Emoji-Mood Scale ratings were strongly related to PROMIS global mental, global physical, fatigue, anxiety, sleep disturbance, and social activity scales ( P < .0001). CONCLUSION: This study provides evidence that scales incorporating emoji are valid for collecting patient-reported outcomes.


  • Open Access

    Employment Characteristics and Risk of Hospitalization Among Older Adults Participating in the Mayo Clinic Biobank

    by Paul Y. Takahashi, Euijung Ryu, Gregory D. Jenkins, Kathleen J. Yost, Christine R. Kirt, Nicole L. Larson, Ruchi Gupta, James R. Cerhan, Janet E. Olson


  • Open Access

    Rates of Asymptomatic COVID-19 Infection and Associated Factors in Olmsted County, Minnesota, in the Prevaccination Era

    by Celine M. Vachon, Aaron D. Norman, Kavita Prasad, Dan Jensen, Gavin M. Schaeferle, Kristy L. Vierling, Meaghan Sherden, Michelle R. Majerus, Katherine A. Bews, Ethan P. Heinzen, et al.


  • Open Access

    Development and Validation of a Kidney-Transplant Specific Measure of Treatment Burden

    by Elizabeth C. Lorenz, Tanya M. Petterson, Isabella Zaniletti, Kandace A. Lackore, Bradley K. Johnson, Martin L. Mai, Sumi S. Nair, Andrew J. Bentall, Kathleen J. Yost, David T. Eton

    Background: Treatment burden refers to the work involved in managing one’s health and its impact on well-being and has been associated with nonadherence in patients with chronic illnesses. No kidney transplant (KT)-specific measure of treatment burden exists. The aim of this study was to develop a KT-specific supplement to the Patient Experience with Treatment and Self-Management (PETS), a general measure of treatment burden. Methods: After drafting and pretesting KT-specific survey items, we conducted a cross-sectional survey study involving KT recipients from Mayo Clinic in Minnesota, Arizona, and Florida. Exploratory factor analysis (EFA) was used to identify domains for scaling the KT-specific supplement. Construct and known-groups validity were determined. Results: Survey respondents (n = 167) had a mean age of 61 years (range 22–86) and received a KT on average 4.0 years ago. Three KT-specific scales were identified (transplant function, self-management, adverse effects). Higher scores on the KT-specific scales were correlated with higher PETS treatment burden, worse physical and mental health, and lower self-efficacy (p < 0.0001). Patients taking more medications reported higher transplant self-management burden. Conclusions: We developed a KT-specific supplement to the PETS general measure of treatment burden. Scores may help providers identify recipients at risk for nonadherence.


  • Patient Experience in Clinical Trials: Quality of Life, Financial Burden, and Perception of Care in Patients With Multiple Myeloma or Lymphoma Enrolled on Clinical Trials Compared With Standard Care

    by Surbhi Sidana, Cristine Allmer, Melissa C. Larson, Amylou Dueck, Kathleen Yost, Rahma Warsame, Gita Thanarajasingam, James R. Cerhan, Jonas Paludo, S. Vincent Rajkumar, et al.

    PURPOSE: Patients' concerns regarding clinical trial (CT) participation include apprehension about side effects, quality of life (QoL), financial burden, and quality of care. METHODS: We prospectively evaluated the experience of patients with multiple myeloma or lymphoma who were treated on CTs (CT group, n = 35) versus patients treated with standard approaches (non-CT group, n = 88) focusing on QoL, financial burden of care, and patients' perception of quality of care over a 1-year period. RESULTS: There were no significant differences in any of the patient-reported outcomes in CT versus non-CT groups. We observed an initial decline in overall QoL in the first 3 months across both groups, driven primarily by physical and functional well-being. QoL gradually improved and was above baseline by month 12. Patients reported highest improvement in the functional well-being subdomain. Patients in both groups reported high satisfaction with the quality of care received, and there were no differences in overall satisfaction, communication with team, or access to care. At baseline, 16%-19% of patients reported financial burden, which increased to a peak of 33% in the CT group and to 49% in the non-CT group over the course of 1 year. There was no significant difference in financial burden in the two groups overall. Most of the patients reported getting all the care that was deemed medically necessary in both groups. However, a significant proportion of patients reported having to make other kinds of financial sacrifices because of their cancer (CT group: 33% of patients at baseline and 21%-40% over 1 year; non-CT group: 19% at baseline and 25%-36% over 1 year). CONCLUSION: Patients treated on CTs reported comparable QoL and quality of care with the non-CT group. A high proportion of patients reported financial burden over time in both groups. Our findings can serve as a guide to educate patients regarding CT participation and highlight the need to address the significant financial burden experienced by patients with cancer.


  • Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis

    by Christopher S. Strouse, Melissa C. Larson, Shawna L. Ehlers, Kathleen J. Yost, Matthew J. Maurer, Stephen M. Ansell, David J. Inwards, Patrick B. Johnston, Ivana N. Micallef, Brian K. Link, et al.

    PURPOSE: This study assessed the long-term quality of life (QOL) of patients with aggressive lymphoma subtypes treated with autologous hematopoietic cell transplant (autoHCT) compared with those without history of transplant. METHODS: Patient-reported QOL measures were prospectively gathered from patients enrolled in the Iowa/Mayo Specialized Program of Research Excellence Molecular Epidemiology Resource cohort with aggressive lymphoma subtypes. QOL was measured using the Functional Assessment of Cancer Therapy-General (FACT-G), Functional Assessment of Chronic Illness Therapy–Fatigue Scale, State-Trait Anxiety Inventory (STAI), and Profile of Mood States instruments and with a numeric rating scale for overall QOL and spiritual QOL. The autoHCT group and no HCT groups were compared at 3 years (FU3) and 6 years (FU6) after lymphoma diagnosis. RESULTS: In total, 980 patients with lymphoma (106 autoHCT and 874 no HCT) diagnosed between 2002 and 2013 were included for analysis. The mean FACT-G total score was similar in the autoHCT and no HCT groups at FU3 (89.9 v 90.1, P = .64) and also at FU6 (91.5 v 89.6, P = .44). No differences between the autoHCT and no HCT groups were identified in the FACT subscales. The STAI identified lower anxiety in the autoHCT group by mean STAI1 (state) at FU3 (30.1 v 33.4, P < .01) and by mean STAI2 (trait) at FU6 (30.1 v 33.5, P = .02). No other clinically meaningful differences were identified between the two groups using the other QOL instruments. CONCLUSION: Patients remaining in remission at 3 and 6 years after diagnosis had a high level of QOL with no significant differences associated with history of treatment with autoHCT.


  • Open Access

    Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant

    by Surbhi Sidana, Amylou C. Dueck, Gita Thanarajasingam, Joan M. Griffin, Carrie Thompson, Urshila Durani, Michelle Burtis, Rahma Warsame, Jonas Paludo, Morie A. Gertz, et al.


  • Open Access

    Predictors of health-related quality of life in patients with colorectal cancer

    by Kathleen J Yost, Elizabeth A Hahn, Alan M Zaslavsky, John Z Ayanian, Dee W West

    Most studies that have identified variables associated with the health-related quality of life (HRQL) of patients with colorectal cancer have been cross-sectional or included patients with other diagnoses. The objectives of this study were to identify predictors of HRQL in patients with colorectal cancer and interpret the clinical importance of the results.


  • A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores

    by Susan Yount, Marcy List, Hongyan Du, Kathleen Yost, Rita Bode, Bruce Brockstein, Athanassios Argiris, Everett Vokes, Ezra E. W. Cohen, Bruce Campbell, et al.

    To evaluate the impact of administration context (embedded versus stand-alone) on the reliability and validity of the FACT Head and Neck Symptom Index (FHNSI). Ninety-eight patients with head and neck cancer were randomized to one of two assessment conditions to evaluate the FHNSI’s context (items administered embedded within the FACT-H&N or as stand-alone scale) and order of administration in the battery. Planned comparisons on the item and scale levels revealed no systematic order or context differences. The embedded and stand-alone versions of the FHNSI showed high internal consistency (Cronbach's alpha 0.79–0.87). Correlations were high between the FHNSI versions and the physical and functional well-being scales of the FACT-H&N (0.70–0.84) and measures of pain intensity (−0.73, −0.74) and depression (−0.71, −0.74); moderate to large with the Performance Status Scale for Head and Neck subscales (PSS-HN; 0.46–0.71); and low with an anxiety measure (0.30, 0.34). Both FHNSI versions differentiated patients grouped by performance status (p < .0001, p < .0001) and global rating of change (p < .0001, p < 0.01). The FHNSI's minimally important difference range was 3–4 points. The FHNSI is a reliable and valid symptom index, which can be administered alone or scored using items embedded within the FACT-H&N.